Cancer Metastasis Through the Lymphovascular System
Therapy-Induced Dormancy and Residual Disease
Publication
, Chapter
Dimarco, AV; Garcia, NMG; Alvarez, JV
January 1, 2022
In many common epithelial cancers, such as breast and prostate cancer, the majority of deaths are caused by the survival and eventual recurrence of residual tumor cells after therapy. In many cases, residual tumors can survive for years or even decades prior to recurrence, suggesting that these tumors are in a dormant state. Because recurrent tumors are often incurable, it is critical to understand how cancer cells survive treatment, persist as residual cells during a prolonged dormant period, and eventually recur. In this chapter, we review the clinical evidence suggesting that dormant residual tumors are an important reservoir for tumor recurrence, and then discuss some of the molecular and cellular features of dormant residual tumors.
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Dimarco, A. V., Garcia, N. M. G., & Alvarez, J. V. (2022). Therapy-Induced Dormancy and Residual Disease. In Cancer Metastasis Through the Lymphovascular System (pp. 97–103). https://doi.org/10.1007/978-3-030-93084-4_10
Dimarco, A. V., N. M. G. Garcia, and J. V. Alvarez. “Therapy-Induced Dormancy and Residual Disease.” In Cancer Metastasis Through the Lymphovascular System, 97–103, 2022. https://doi.org/10.1007/978-3-030-93084-4_10.
Dimarco AV, Garcia NMG, Alvarez JV. Therapy-Induced Dormancy and Residual Disease. In: Cancer Metastasis Through the Lymphovascular System. 2022. p. 97–103.
Dimarco, A. V., et al. “Therapy-Induced Dormancy and Residual Disease.” Cancer Metastasis Through the Lymphovascular System, 2022, pp. 97–103. Scopus, doi:10.1007/978-3-030-93084-4_10.
Dimarco AV, Garcia NMG, Alvarez JV. Therapy-Induced Dormancy and Residual Disease. Cancer Metastasis Through the Lymphovascular System. 2022. p. 97–103.